If you have a kidney or bladder problem, you might have a chance of being able to get calcium phosphate tablets from the drug manufacturer, according to a new study.
The researchers found that people who take more than 100 tablets daily can increase their chances of survival by up to a third.
“If you have an existing kidney or urinary tract problem, then these calcium phosphate capsules could help,” said lead author Sarah Schmitt, a doctoral student in clinical pharmacology at the University of Wisconsin at Madison.
“The downside of this is that it might not be very effective if you’re on a long-term regimen.”
People on a regimen of calcium phosphate pills, which typically include 10, 20, or 50 tablets, should consume about 200 to 250 mg per day, or about the amount of a bottle of mineral water, according with the researchers.
The new study looked at a database of nearly 1.4 million people who took part in a study published in the Journal of the American Medical Association on April 13.
Of those, about 10 percent had a history of kidney or ureter stones.
Those who took more than one type of calcium supplement were more likely to be older and had higher rates of kidney disease.
They were also more likely than other people to be male and have diabetes, heart disease, cancer, high blood pressure, and high cholesterol.
People who took less than one calcium supplement or no calcium at all were less likely to have kidney or renal disease and had a lower risk of kidney stone formation.
“These results suggest that taking calcium phosphate can be effective and should be a priority for people who have kidney problems,” Schmitt said.
“This is the first study to compare calcium phosphate and calcium citrate tablets and to compare them to other calcium supplements, which are currently available.”
Schmitt is a doctoral candidate in clinical pharmaat the University at Madison and was also involved in the development of the calcium phosphate tablet.
The study, “Long-Term Use of Calcium Citrate for the Prevention of Stone Formation in Elderly Persons,” was supported by the National Institutes of Health (grant R01 AI064580 and AI096978), the National Institute of Neurological Disorders and Stroke (grants R01 NS063942 and AI106637), the U.S. Army Medical Research Institute of Infectious Diseases (granted R01 GM110169 and AI0382217), the American Diabetes Association, the National Cancer Institute, the United States Army Medical Corps, the Department of Veterans Affairs, and the Uppsala University.
The Uppsalaberg Research Institute and the University Hospitals Krefelds Klinikum are affiliated with the Department for Medical Research and Innovation at the Umeå University of Technology.
This story was provided by Vice News, a nonprofit news service that covers the intersection of business and culture.